Incyte (INCY) Reports Positive 52-Wk Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo
Tweet Send to a Friend
Incyte (NASDAQ: INCY) today announces positive 52-week results from its randomized, double-blind, dose-ranging, Phase 2 study evaluating ruxolitinib cream, a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
